Anti-TNF therapy is also believed to ameliorate aberrant changes in TNFR1-dependent pathways by preventing canonical NF-κB pathway activation and cell death of affected tissue, such as the gut epithelium in IBD and the synovium in RA. The gene discussed is NFKB1; the disease is inflammatory bowel disease.